EQ302 / Equillium - LARVOL DELTA

Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter. (Equillium Bio Press Release) - "Continuing to advance EQ504, a potent and selective AhR modulator with potential for targeted local delivery in gastrointestinal (GI) diseases, including UC, as well as inhaled formulations for inflammatory lung diseases. Equillium recently presented two EQ504 abstracts at IMMUNOLOGY 2026, the annual meeting of the American Association of Immunologists in April 2026. Preclinical findings demonstrate that EQ504 promotes immune tolerance through induction of IL-10 and IL-22, supports anti-inflammatory macrophage polarization, and enhances epithelial repair and barrier function. Evaluating further advancement of EQ302, its oral, bi-specific inhibitor of IL-15 and IL-21 being developed for GI indications, including celiac disease."

New P1 trial • P1 data • Preclinical • Celiac Disease • Inflammatory Bowel Disease • Ulcerative Colitis

Equillium (NASDAQ: EQ) expands autoimmune pipeline and raises $65M in private financings (StockTitan.net) - "The company reports two sizable private placements: about $30.0 million in August 2025 plus $35.0 million in March 2026, with up to $20.0 million more contingent on milestones. Management believes this cash extends the runway into 2029, giving time to execute a Phase 1 program for EQ504 and advance EQ302 manufacturing and toxicology work...Risks remain typical for early-stage biotech: continued losses, dependence on additional capital, regulatory uncertainty, manufacturing reliance on CMOs, and potential Nasdaq listing compliance issues. Future disclosures on the planned mid‑2026 Phase 1 start for EQ504 and subsequent data readout will be key to assessing progress."

Financing • New P1 trial • Celiac Disease • Ulcerative Colitis

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights (Businesswire) - P2 | N=36 | NCT05589610 | Sponsor: Equillium | "Announced positive topline data from Phase 2 study of EQ101 in alopecia areata subjects, including 29% of completed subjects with moderate to severe disease achieving SALT (Severity Alopecia Tool) ≤ 20....Anticipated Upcoming Milestones: EQ101: Transition to subcutaneous delivery and initiate Phase 2 dose optimization study in alopecia areata – 2025. EQ302: Initiate Phase 1 study – 2H 2025....Revenue for the second quarter of 2024 was $13.9 million, compared to $9.1 million during the same period in 2023. Revenue in the second quarters of 2024 and 2023 consisted entirely of itolizumab development funding and amortization of the upfront payment resulting from the Asset Purchase Agreement with Ono.

Commercial • New P2 trial • P2 data • Acute Graft versus Host Disease • Alopecia • Immunology

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium (Businesswire) - "Equillium Inc...announced a presentation at the 18th Annual Peptide Therapeutics Symposium highlighting EQ302, a second generation orally deliverable multi-cytokine inhibitor in development to target IL-15 and IL-21....The presentation outlines the origins of EQ302 from its parent peptide, EQ102, which was originally modeled from the D-helix of the IL-2 family of cytokines and binds directly to CD132 to inhibit the signaling of IL-15 and IL-21....EQ302 delivered to mice via oral gavage can inhibit IL-15-induced IFNγ transcription locally in the GI tract indicating potential utility for Celiac Disease and inflammatory bowel disease.​"

Preclinical • Celiac Disease • Inflammatory Bowel Disease